Vaccines are developed to address the public health needs. In China, vaccines are available through the government programmed called “Expanded Program on Immunization” at free for all children up to 14 years of age. However private sector vaccines such as Rabies Vaccine, Influenza Vaccine and Haemophilus Influenza Type B vaccine are also available in China but are usually paid for out-of-pocket as these are neither include in government EPI program nor government health insurance schemes. China Vaccine Market has great potential due to its vast population; so, its market size is projected to cross over US$ 9 Billion by 2025.
Request a free Sample copy of the report: https://www.renub.com/request-sample-page.php?gturl=china-vaccine-market-p.php
China vaccine market is divided into public and private vaccine market. Public market is classified by Category 1 whereas and Private vaccines included in Category 2. Vaccines in the public market are regulated by PRC government and generally given free of cost by provincial CDC whereas private vaccine market is dominating by private vaccine companies. As a result, private vaccines prices are higher. China vaccine market has faced several scandals in past couple of years which certainly hinder the vaccine market growth.
Renub Research report titled “China Vaccine Market & Doses Forecast By Sector (Private, Public), Disease Type (Meningococcal Meningitis, Pneumococcal, DTP, Ebola, Rabies, Others), Products (MCV4, MPSV4, MCV2-Hib, MCV2, MPSV2 and Men A, PCV13, PPV23, Others), Company (Sinopharm Group, Sinovac Biotech, Beijing Tiantan Biological Products Corp Ltd, Chongqing Zhifei Biological Products Co Ltd, Hualan Biological Engineering Inc, Liaoning Chengda Co Ltd, Walvax Biotechnology Co Ltd)” provides a complete analysis of China Vaccine Market.
Sectors – Vaccine Market & Doses in China
Disease Type Market – Meningococcal Meningitis, Pneumococcal and DTP Vaccine Market has significant Market Share in China Vaccine Market
On the basis of disease type, Meningococcal meningitis, Pneumococcal and DTP Vaccine market is expected to control major portion of China vaccine market. Vaccine market in China is segmented into Meningococcal meningitis, Pneumococcal, DTP, Ebola, Rabies & Others.
Products – PCV13 Drives Vaccine Market in China
In terms of products, PCV13 hold the maximum share of the China vaccine market. It is predicted that PCV13 will maintain their leading place during the forecasting period as well. Products included in this report are as follows:
• MPSV2 and Men A
Request a free Brochure copy of the report: https://www.renub.com/request-brochure-page.php?gturl=china-vaccine-market-p.php
Email: [email protected]
Follow us on LinkedIn: www.linkedin.com/company/renub-research